Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 66
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Front Immunol ; 12: 643240, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33679806

RESUMEN

Dendritic cells (DCs) are well-established as major players in the regulation of immune responses. They either induce inflammatory or tolerogenic responses, depending on the DC-subtype and stimuli they receive from the local environment. This dual capacity of DCs has raised therapeutic interest for their use to modify immune-activation via the generation of tolerogenic DCs (tolDCs). Several compounds such as vitamin D3, retinoic acid, dexamethasone, or IL-10 and TGF-ß have shown potency in the induction of tolDCs. However, an increasing interest exists in defining tolerance inducing receptors on DCs for new targeting strategies aimed to develop tolerance inducing immunotherapies, on which we focus particular in this review. Ligation of specific cell surface molecules on DCs can result in antigen presentation to T cells in the presence of inhibitory costimulatory molecules and tolerogenic cytokines, giving rise to regulatory T cells. The combination of factors such as antigen structure and conformation, delivery method, and receptor specificity is of paramount importance. During the last decades, research provided many tools that can specifically target various receptors on DCs to induce a tolerogenic phenotype. Based on advances in the knowledge of pathogen recognition receptor expression profiles in human DC subsets, the most promising cell surface receptors that are currently being explored as possible targets for the induction of tolerance in DCs will be discussed. We also review the different strategies that are being tested to target DC receptors such as antigen-carbohydrate conjugates, antibody-antigen fusion proteins and antigen-adjuvant conjugates.


Asunto(s)
Presentación de Antígeno , Células Dendríticas/inmunología , Tolerancia Inmunológica , Inmunoterapia , Receptores de Superficie Celular/inmunología , Linfocitos T Reguladores/inmunología , Humanos , Interleucina-10/inmunología , Factor de Crecimiento Transformador beta/inmunología
2.
Trop Biomed ; 38(4): 476-483, 2021 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-35001914

RESUMEN

Parasite immune response against schistosomal antigens involves both the innate and adaptive immune response. Tregs have a suppressive effect and play a role on the parasite's immune evasion. This study aimed to evaluate active compounds of Allium sativum (AS) ethanol extract and the impact of AS extract alone or in combination with praziquantel on Tregs and anti-inflammatory cytokines TGF- ß and IL-10 in mice infected with S. mansoni . Phytochemical screening of AS bulbs for various active constituents and qualitative and quantitative analysis of the flavonoids and phenolic acids were done using HPLC. Measurement of splenocytes Treg cell phenotypes and anti-inflammatory cytokines TGF- ß and IL-10 was done by flow cytometric analysis. The data are expressed as mean ± SD. Statistical significance was determined by one-way ANOVA utilizing the statistical package (SPSS version 17.0). HPLC of AS ethanol extract revealed presence of 22 and 18 compounds of flavonoids and phenolic acids, respectively. S. mansoni infection upregulated the Treg cells subsets (CD4, CD25, Foxp3) frequencies and the levels of TGF- ß and IL-10 anti-inflammatory cytokines when compared to healthy control. AS ethanol extract alone or combined with PZQ decreases the production of Treg cells from spleen in addition to the reduction in anti- inflammatory cytokines IL-10 and TGF- ß. This study recommends that the combination of AS ethanol extract and PZQ may play a role in maintaining the homeostasis of the immune system during schistosomiasis by decreasing Tr eg cells and anti-inflammatory cytokines IL- 10 and TGF- ß production.


Asunto(s)
Citocinas/inmunología , Ajo , Extractos Vegetales , Esquistosomiasis , Linfocitos T Reguladores/inmunología , Animales , Etanol , Flavonoides/farmacología , Ajo/química , Hidroxibenzoatos/farmacología , Interleucina-10/inmunología , Ratones , Extractos Vegetales/farmacología , Esquistosomiasis/tratamiento farmacológico , Esquistosomiasis/inmunología , Factor de Crecimiento Transformador beta/inmunología
3.
J Neuroimmunol ; 347: 577358, 2020 10 15.
Artículo en Inglés | MEDLINE | ID: mdl-32795734

RESUMEN

Bone Morphogenetic Proteins (BMP) and Transforming Growth Factor-beta (TGF-ß) are cytokines with similar receptors and messengers. They are important for immune cell function, with BMPs exerting mainly proinflammatory but also anti-inflammatory effects, and TGF-ß suppressing inflammation. Patients with Multiple Sclerosis exhibit BMP overactivity and suppressed TGF-ß signaling. This dysregulated signaling participates in the crosstalk between infiltrating immune cells and glia, where BMP inhibits remyelination. Reciprocal antagonism between the two pathways takes place via a variety of mechanisms. Although this antagonism has not been studied in the setting of Multiple Sclerosis, it could inform further research and treatment discovery.


Asunto(s)
Proteínas Morfogenéticas Óseas/inmunología , Esclerosis Múltiple/inmunología , Transducción de Señal/fisiología , Factor de Crecimiento Transformador beta/inmunología , Animales , Proteínas Morfogenéticas Óseas/metabolismo , Humanos , Esclerosis Múltiple/metabolismo , Factor de Crecimiento Transformador beta/metabolismo
4.
Biomed Pharmacother ; 128: 110316, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32505821

RESUMEN

BACKGROUND: Pudilan (PDL), a four-herb prescription with the traditional function of heat-clearing and detoxifying, has been clinically used as an anti-SARS-CoV-2 infectory agent in China. PDL might also have therapeutic potentials for COVID-19 while the underlying mechanisms remain to be clarified. METHODS: We used network pharmacology analysis and selected 68 co-targeted genes/proteins as targets of both PDL and COVID-19. These co-targeted genes/proteins were predicted by SwissDock Server for their high-precision docking simulation, and analyzed by STRING for proteins to protein interaction (PPI), pathway and GO (gene ontology) enrichment. The therapeutic effect for PDL treatment on COVID-19 was validated by the TCMATCOV (TCM Anti COVID-19) platform. RESULTS: PDL might prevent the entrance of SARS-CoV-2 entry into cells by blocking the angiotensin-converting enzyme 2 (ACE2). It might inhibit the cytokine storm by affecting C-reactive protein (CRP), interferon-γ (IFN-γ), interleukin- 6 (IL-6), interleukin- 10 (IL-10), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), C-C motif chemokine ligand 5 (CCL5), transforming growth factor-ß1 (TGFß1), and other proteins. PDL might moderate the immune system to shorten the course of the disease, delay disease progression, and reduce the mortality rate. CONCLUSION: PDL might have a therapeutic effect on COVID-19 through three aspects, including the moderate immune system, anti-inflammation, and anti-virus entry into cells.


Asunto(s)
Antivirales/farmacología , Betacoronavirus , Infecciones por Coronavirus , Síndrome de Liberación de Citoquinas , Medicamentos Herbarios Chinos/farmacología , Pandemias , Neumonía Viral , Internalización del Virus/efectos de los fármacos , Enzima Convertidora de Angiotensina 2 , Inhibidores de la Enzima Convertidora de Angiotensina/farmacología , Antiinflamatorios/farmacología , Betacoronavirus/efectos de los fármacos , Betacoronavirus/aislamiento & purificación , COVID-19 , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/inmunología , Síndrome de Liberación de Citoquinas/tratamiento farmacológico , Síndrome de Liberación de Citoquinas/inmunología , Humanos , Factores Inmunológicos/farmacología , Interferón gamma/inmunología , Interleucinas/inmunología , Simulación del Acoplamiento Molecular , Peptidil-Dipeptidasa A/metabolismo , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/inmunología , Mapas de Interacción de Proteínas , SARS-CoV-2 , Factor de Crecimiento Transformador beta/inmunología
5.
Fish Shellfish Immunol ; 100: 171-178, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-32135345

RESUMEN

A six-week feeding trial was carried out to evaluate the effects of inclusion of dietary olive waste cake (OWC, 0, 0.5, 2.5 and 5 g kg-1 diet) on performance, antioxidant condition and immune responses of rainbow trout (Oncorhynchus mykiss) (2.5 ± 0.1 g). Supplementing diet with 2.5 and 5 g OWC kg-1 diet significantly enhanced serum and mucosal lysozyme activity in fish. Regarding mucosal immunity, fish fed 2.5 and 5 g OWC kg-1 diets had higher skin mucus total Ig concentrations than other groups. In relation to antioxidant status, those in 2.5 g OWC kg-1 and the control groups exhibited the highest and the least liver superoxide dismutase and glutathione peroxidase activities, respectively. Furthermore, the activity of liver glutathione S transferase in fish fed 2.5 and 5 g OWC kg-1 diets was higher than the other treatments. In respect to gut cytokines gene expression, our findings demonstrated dietary OWC did not influence interlukines-1ß and 10 genes expression, but relative expression of IL8 gene gradually up-regulated with increasing dietary OWC level. Moreover, fish fed 0.5 g OWC kg-1 and the control diets had the highest and the lowest gut tumor necrosis factor-α gene expression values, respectively. The relative expression of transforming growth factor-ß significantly down-regulated in gut of fish fed 2.5 and 5 g OWC kg-1 diets compared to other groups. Supplementing diet with OWC pronouncedly improved growth and feed conversion ratio in fish compared to the control. Overall, the findings of this study suggested that inclusion of 2.5 g OWC kg-1 diet can improve growth rate, oxidative stress status, humoral and skin mucosal immune responses in O. mykiss fingerlings and it can be considered as a functional feed additive for this species.


Asunto(s)
Inmunidad Humoral/genética , Inmunidad Mucosa/genética , Olea/química , Oncorhynchus mykiss/inmunología , Alimentación Animal , Animales , Antioxidantes , Suplementos Dietéticos , Resistencia a la Enfermedad , Expresión Génica , Residuos Industriales , Moco/inmunología , Muramidasa/metabolismo , Oncorhynchus mykiss/genética , Piel/inmunología , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/inmunología , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/inmunología
6.
J Asthma ; 57(6): 670-679, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-30943821

RESUMEN

Introduction: Homeopathy is a therapeutic method based on the fundamental principle of "like cures like." Homeopathic remedies are extremely dilute but involve vigorous shaking at each dilution. Isopathy is one approach of homeopathy, in which the causative agents or products of a disease are used to treat the same disease. Allergen immunotherapy is the only potential disease-modifying treatment for allergic patients. Subcutaneous immunotherapy is more effective than sublingual immunotherapy. However, subcutaneous immunotherapy is ineffective at a low dose, whereas at high doses it can result in an unacceptably high frequency of systemic reactions. In the current study, we evaluated the efficacy of isopathic immunotherapy with highly diluted ovalbumin (HD OVA) in the treatment of OVA-induced allergic asthma in BALB/c mice.Methods: BALB/c mice were sensitized with OVA and alum. Two weeks later, the mice received HD OVA on days 21, 22, 32 and 41 (8 h after the last challenge) of the treatment. The mice were challenged with OVA (5%) aerosols on days 35, 38 and 41 for 20 minutes using an ultrasonic nebulizer and sacrificed the next day.Results: Isopathic immunotherapy significantly reduced lung tissue inflammation, the number of eosinophils in bronchoalveolar fluid, allergen-specific IgE and interleukin-4 production. It also insignificantly increased the production of transforming growth factor-beta and proliferation of regulatory T cells against the allergen.Conclusion: Isopathic immunotherapy may be a good candidate treatment for allergic asthma.


Asunto(s)
Asma/terapia , Desensibilización Inmunológica/métodos , Alérgenos , Compuestos de Alumbre , Animales , Asma/sangre , Asma/inmunología , Asma/patología , Líquido del Lavado Bronquioalveolar/citología , Líquido del Lavado Bronquioalveolar/inmunología , Inmunoglobulina E/sangre , Interleucina-4/inmunología , Pulmón/patología , Masculino , Ratones Endogámicos BALB C , Ovalbúmina , Bazo/citología , Bazo/inmunología , Linfocitos T Reguladores/inmunología , Factor de Crecimiento Transformador beta/inmunología , Resultado del Tratamiento
7.
Biochem Biophys Res Commun ; 522(3): 743-748, 2020 02 12.
Artículo en Inglés | MEDLINE | ID: mdl-31791581

RESUMEN

Rheumatoid arthritis is a chronic and systemic autoimmune disease, which affects approximately 1% of the adult population worldwide. The present study investigated the therapeutic effect of theacrine (TC) on arthritis and its mechanisms in Freund's incomplete adjuvant (FIA)-induced SD rats. Rats were randomly divided into 5 groups: i) healthy control; ii) model; iii) positive control with methotrexate (MTX); iv) treatment with 12.5 mg/kg TC; and v) treatment with 25.0 mg/kg TC. The apparent scores, including changes in body weights, degree of paw swelling and arthritis indicators, were analyzed to evaluate the anti-chronic inflammatory effect of TC. The levels of interleukin (IL)-6 and transforming growth factor-ß (TGF-ß) in serum were measured by enzyme-linked immunosorbent assay. The protein and RNA expression levels of the critical factors in rats were measured to elucidate the mechanisms responsible for chronic inflammation and to verify molecular indexes of chronic inflammatory conditions. TC notably suppressed the severity of FIA-induced rat by attenuating the apparent scores, animal weight and inflammatory indexes in the 25 mg/kg TC group compared with the FIA rat model. Furthermore, TC significantly decreased the levels of IL-6 and increased the levels of TGF-ß. Histopathological examinations indicated that TC rescued the synovial hyperplasia and inflammatory cell infiltration in joint tissues. In addition, TC enhanced TGF-ß-mediated shifts in inflammatory marker expression in joint tissue. Overall, the present study demonstrated that TC exerted a superior anti-arthritic effect via the suppression of IL-6 and the activation of TGF-ß by the TGF-ß/SMAD pathway.


Asunto(s)
Antiinflamatorios/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Proteínas Smad/inmunología , Factor de Crecimiento Transformador beta/inmunología , Ácido Úrico/análogos & derivados , Animales , Artritis Experimental/inducido químicamente , Artritis Experimental/tratamiento farmacológico , Artritis Experimental/inmunología , Artritis Experimental/patología , Artritis Reumatoide/inducido químicamente , Artritis Reumatoide/inmunología , Artritis Reumatoide/patología , Enfermedad Crónica , Adyuvante de Freund , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Inflamación/inmunología , Inflamación/patología , Articulaciones/efectos de los fármacos , Articulaciones/inmunología , Articulaciones/patología , Lípidos , Ratas , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacos , Proteínas Smad/análisis , Factor de Crecimiento Transformador beta/análisis , Ácido Úrico/uso terapéutico
8.
Drug Deliv Transl Res ; 9(6): 1027-1042, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31115868

RESUMEN

The balance between M1 and M2 macrophages plays an important role in wound healing. Interestingly, this immune response can be modulated by natural biomaterials such as chitosan nanohydrogel (Ch) and aloe vera (AV). Therefore, we aimed to improve wound recovery response by exploiting the potential healing properties of Ch and AV. Wounds were created in rats and were treated daily with either saline (control), AV, Ch, or different ratios of AV (volume):Ch (weight) (1:1), (2:1), and (3:1). M1 (iNOS, TNF-α) and M2 (CD163, TGF-ß) responses were analyzed at days 3, 7, 14, 21, and 28. Wound healing increased within the third and seventh days in AV-Ch (3:1) (P < 0.001 and P < 0.002, respectively). In the treated groups, immunohistochemistry of iNOS expression decreased on the third day (P < 0.0001) while CD163 increased (P < 0.0001) on the 3rd, 7th, and 14th days. The gene expression of TGF-ß decreased on the third day in AV group (P < 0.03) and on the 21st and 28th days in Ch-treated group (P < 0.00). TNF-α expression decreased in AV, Ch, and AV-Ch (3:1 v/w) on the 14th and 28th days (P < 0.00). TGF-ß and TNF-α proteins decreased on the 28th day compared to the control and AV-Ch (3:1 v/w), respectively. AV-Ch (1 and 3:1 v/w) and Ch resulted in optimum wound repair by decreasing M1 after 3 days and increasing M2 after 14. Thus, Ch nanohydrogel, especially in combination with 1:1 and 1:3 ratio to AV, could be a proper candidate for modulating macrophages in response to wound healing.


Asunto(s)
Quitosano/administración & dosificación , Portadores de Fármacos/administración & dosificación , Hidrogeles/administración & dosificación , Macrófagos/efectos de los fármacos , Nanopartículas/administración & dosificación , Preparaciones de Plantas/administración & dosificación , Cicatrización de Heridas/efectos de los fármacos , Animales , Antibacterianos/administración & dosificación , Antifúngicos/administración & dosificación , Bacterias/efectos de los fármacos , Bacterias/crecimiento & desarrollo , Hongos/efectos de los fármacos , Hongos/crecimiento & desarrollo , Macrófagos/inmunología , Masculino , Óxido Nítrico Sintasa de Tipo II/inmunología , Ratas Wistar , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/inmunología , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/inmunología
9.
Clin Exp Nephrol ; 23(7): 880-889, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-30830549

RESUMEN

BACKGROUND: Individuals who have kidney disease or kidney transplants need routine assessment of their kidney damage and function, which are largely measured based on histological examination of kidney biopsies, blood test, and urinalysis. These methods are practically difficult or inconvenient, and expensive. The objective of this study was to develop a model to estimate the kidney damage and function by surface-enhanced Raman spectroscopy (SERS). METHODS: Urine samples were collected from two previous studies: renal allograft recipient Lewis rats receiving anti-TGF-ß antibody or control antibody treatment and obese diabetic ZSF1 rats with kidney disease fed with whole grape powder-containing chow or control chow. Silver nanoparticle-based SERS spectra of urine were measured. SERS spectra were analyzed using principal component analysis (PCA) combined with linear discriminant analysis (LDA) and partial least squires (PLS) analysis. RESULTS: PCA/LDA separated anti-TGF-ß antibody-treated group from control group with 90% sensitivity and 70% specificity in kidney transplants, and grape-fed group from controls with 72.7% sensitivity and 60% specificity in diabetic kidneys. The receiver operating characteristic curves showed that the integration area under the curve was 0.850 ± 0.095 (p = 0.008) in kidney transplant groups and 0.800 ± 0.097 (p = 0.02) in diabetic kidney groups. PLS predicted the biochemical parameters of kidney function using the SERS spectra, resulting in R2 = 0.8246 (p < 0.001,urine protein), R2 = 0.8438 (p < 0.001, urine creatinine), R2 = 0.9265 (p < 0.001, urea), R2 = 0.8719 (p < 0.001, serum creatinine), and R2 = 0.6014 (p < 0.001, urine protein to creatinine ratio). CONCLUSION: Urine SERS spectral analysis suggesting that it may become a convenient method for rapid assessment of renal impairment.


Asunto(s)
Rechazo de Injerto/diagnóstico , Enfermedades Renales/diagnóstico , Pruebas de Función Renal , Trasplante de Riñón/efectos adversos , Riñón/metabolismo , Espectrometría Raman , Animales , Anticuerpos/farmacología , Biomarcadores/orina , Suplementos Dietéticos , Modelos Animales de Enfermedad , Rechazo de Injerto/tratamiento farmacológico , Rechazo de Injerto/etiología , Rechazo de Injerto/orina , Riñón/efectos de los fármacos , Enfermedades Renales/tratamiento farmacológico , Enfermedades Renales/etiología , Enfermedades Renales/orina , Extractos Vegetales/farmacología , Valor Predictivo de las Pruebas , Ratas Endogámicas Lew , Ratas Zucker , Reproducibilidad de los Resultados , Factor de Crecimiento Transformador beta/antagonistas & inhibidores , Factor de Crecimiento Transformador beta/inmunología , Urinálisis , Vitis
10.
Int J Mol Sci ; 19(11)2018 Nov 03.
Artículo en Inglés | MEDLINE | ID: mdl-30400326

RESUMEN

The use of inorganic calcium/phosphate supplemented with biopolymers has drawn lots of attention in bone regenerative medicine. While inflammation is required for bone healing, its exacerbation alters tissue regeneration/implants integration. Inspired by bone composition, a friendly automated spray-assisted system was used to build bioactive and osteoinductive calcium phosphate/chitosan/hyaluronic acid substrate (CaP-CHI-HA). Exposing monocytes to CaP-CHI-HA resulted in a secretion of pro-healing VEGF and TGF-ß growth factors, TNF-α, MCP-1, IL-6 and IL-8 pro-inflammatory mediators but also IL-10 anti-inflammatory cytokine along with an inflammatory index below 1.5 (versus 2.5 and 7.5 following CaP and LPS stimulation, respectively). Although CD44 hyaluronic acid receptor seems not to be involved in the inflammatory regulation, results suggest a potential role of chemical composition and calcium release from build-up substrates, in affecting the intracellular expression of a calcium-sensing receptor. Herein, our findings indicate a great potential of CaP-CHI-HA in providing required inflammation-healing balance, favorable for bone healing/regeneration.


Asunto(s)
Sustitutos de Huesos/farmacología , Fosfatos de Calcio/farmacología , Quitosano/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Ácido Hialurónico/farmacología , Regeneración Ósea/genética , Regeneración Ósea/inmunología , Sustitutos de Huesos/química , Huesos/citología , Huesos/metabolismo , Fosfatos de Calcio/química , Quimiocina CCL2/genética , Quimiocina CCL2/inmunología , Quitosano/química , Regulación de la Expresión Génica/inmunología , Humanos , Receptores de Hialuranos/genética , Receptores de Hialuranos/inmunología , Ácido Hialurónico/química , Inflamación , Interleucinas/genética , Interleucinas/inmunología , Mitocondrias/efectos de los fármacos , Mitocondrias/inmunología , Mitocondrias/metabolismo , Especies Reactivas de Oxígeno/inmunología , Especies Reactivas de Oxígeno/metabolismo , Receptores Sensibles al Calcio/genética , Receptores Sensibles al Calcio/inmunología , Transducción de Señal , Células THP-1 , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/inmunología , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/inmunología , Factor A de Crecimiento Endotelial Vascular/genética , Factor A de Crecimiento Endotelial Vascular/inmunología , Vinculina/genética , Vinculina/inmunología
11.
Nat Commun ; 9(1): 2611, 2018 07 04.
Artículo en Inglés | MEDLINE | ID: mdl-29973593

RESUMEN

Tumor-derived soluble factors promote the production of Gr-1+CD11b+ immature myeloid cells, and TGFß signaling is critical in their immune suppressive function. Here, we report that miR-130a and miR-145 directly target TGFß receptor II (TßRII) and are down-regulated in these myeloid cells, leading to increased TßRII. Ectopic expression of miR-130a and miR-145 in the myeloid cells decreased tumor metastasis. This is mediated through a downregulation of type 2 cytokines in myeloid cells and an increase in IFNγ-producing cytotoxic CD8 T lymphocytes. miR-130a- and miR-145-targeted molecular networks including TGFß and IGF1R pathways were correlated with higher tumor stages in cancer patients. Lastly, miR-130a and miR-145 mimics, as well as IGF1R inhibitor NT157 improved anti-tumor immunity and inhibited metastasis in preclinical mouse models. These results demonstrated that miR-130a and miR-145 can reprogram tumor-associated myeloid cells by altering the cytokine milieu and metastatic microenvironment, thus enhancing host antitumor immunity.


Asunto(s)
Regulación Neoplásica de la Expresión Génica , Inmunidad Innata/efectos de los fármacos , Neoplasias Pulmonares/genética , Neoplasias Mamarias Experimentales/genética , MicroARNs/genética , Receptor Tipo II de Factor de Crecimiento Transformador beta/genética , Animales , Antineoplásicos/farmacología , Antígeno CD11b/genética , Antígeno CD11b/inmunología , Linfocitos T CD8-positivos/efectos de los fármacos , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/patología , Línea Celular Tumoral , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Inyecciones Intravenosas , Interferón gamma/genética , Interferón gamma/inmunología , Neoplasias Pulmonares/inmunología , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/terapia , Neoplasias Mamarias Experimentales/inmunología , Neoplasias Mamarias Experimentales/patología , Neoplasias Mamarias Experimentales/terapia , Ratones , Ratones Transgénicos , MicroARNs/inmunología , Células Mieloides/efectos de los fármacos , Células Mieloides/inmunología , Células Mieloides/patología , Oligorribonucleótidos/administración & dosificación , Oligorribonucleótidos/genética , Oligorribonucleótidos/metabolismo , Pirogalol/análogos & derivados , Pirogalol/farmacología , Receptor IGF Tipo 1/antagonistas & inhibidores , Receptor IGF Tipo 1/genética , Receptor IGF Tipo 1/inmunología , Receptor Tipo II de Factor de Crecimiento Transformador beta/inmunología , Receptores de Quimiocina/genética , Receptores de Quimiocina/inmunología , Transducción de Señal , Sulfonamidas/farmacología , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/inmunología
12.
Int J Mol Sci ; 19(7)2018 Jun 21.
Artículo en Inglés | MEDLINE | ID: mdl-29933541

RESUMEN

Bai Xuan Xia Ta Re Pian (BXXTR) is a traditional Uighur medicine ancient prescription in China widely used in the treatment of psoriasis, presenting a high curative rate and few side effects. Given that the active constituents and action mechanism still remain unclear, the aim of this study is to explore the potential active constituents and mechanism of antipsoriasis of BXXTR. Psoriasis-like lesions model in BALB/c mice was induced by Imiquimod (IMQ), including five treatment groups: control group, IMQ-treated group, IMQ-ACITRETIN group (Positive control group), IMQ-BXXTR low dose group, IMQ-BXXTR medium dose group and IMQ-BXXTR high dose group. The Psoriasis Area and Severity Index (PASI) score, skin and ear thickness, and histologic section were collected. The differentially expressed genes were determined by using RNAseq technology and the relevant pathways were analyzed by KEGG database. The ELISA kit and western blot assays were used to detect the related protein expression levels. In addition, the chemical constituents of BXXTR were determined by UPLC-TOF-MS analysis and the potential active constituents were predicted by SEA DOCK and Gene Ontology (GO). The data demonstrated that BXXTR significantly alleviated IMQ-induced psoriasis. RNA-seq analysis showed that BXXTR induced the expression levels of 31 genes; the KEGG analysis suggested that BXXTR could significantly change IL-17-related inflammatory pathways. The ELISA kit confirmed that the expression level of IL-17A protein was significantly reduced. 75 compounds of BXXTR were determined by UPLC-TOF-MS analysis, 11 of 75 compounds were identified as potential active compounds by similarity ensemble approach docking (SEA DOCK) and Gene Ontology (GO). BXXTR reduced the severity of skin lesions by inhibiting IL-17-related inflammatory pathways. The results indicated that BXXTR could suppress psoriasis inflammation by multiple-constituents-regulated multiple targets synergistically. Collectively, this study could provide important guidance for the elucidation of the active constituents and action mechanism of BXXTR for the treatment of psoriasis.


Asunto(s)
Fármacos Dermatológicos/farmacología , Medicamentos Herbarios Chinos/farmacología , Queratinocitos/efectos de los fármacos , Psoriasis/tratamiento farmacológico , Piel/efectos de los fármacos , Aminoquinolinas , Animales , Proliferación Celular , Fármacos Dermatológicos/química , Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/química , Regulación de la Expresión Génica , Humanos , Imiquimod , Interleucina-17/genética , Interleucina-17/inmunología , Interleucina-18/genética , Interleucina-18/inmunología , Interleucina-23/genética , Interleucina-23/inmunología , Queratinocitos/inmunología , Queratinocitos/patología , Masculino , Medicina Tradicional China/métodos , Ratones , Ratones Endogámicos BALB C , Psoriasis/inducido químicamente , Psoriasis/inmunología , Psoriasis/patología , Índice de Severidad de la Enfermedad , Transducción de Señal , Piel/inmunología , Piel/patología , Receptor Toll-Like 8/genética , Receptor Toll-Like 8/inmunología , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/inmunología , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/inmunología
13.
Int J Mol Med ; 42(2): 745-754, 2018 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-29717774

RESUMEN

The present study aimed to investigate the anti­arthritic effect of physcion 8­O­ß­glucopyranoside (POGD) and its possible mechanisms. The anti­proliferative effects of POGD on MH7A cells were detected using a CCK­8 assay, and the release of pro­inflammatory cytokines, interleukin (IL)­1ß, IL­6, IL­8, IL­12 and IL­17A, were determined by ELISA. A type II collagen­induced arthritis (CIA) rat model was established to evaluate the anti­arthritic effect of POGD in vivo. The paw volumes, arthritis indices and serum levels of tumor necrosis factor (TNF)­α, IL­1ß, IL­6, IL­8, IL­17A were determined by ELISA. The mRNA expression levels of matrix metalloproteinase (MMP)­2, MMP­3, MMP­9, vascular endothelial growth factor and cyclooxygenase­2 were determined by reverse transcription­quantitative polymerase chain reaction analysis, and the expression levels of transforming growth factor (TGF)­ß1, small mothers against decapentaplegic (Smad)4, Smad7, c­Jun N­terminal kinase (JNK), phosphorylated (p­)JNK, p­P38, P38, p­extracellular signal­regulated kinase (ERK)1/2, ERK1/2, nuclear factor (NF)­κB p65 in the nucleus (N), cytosolic NF­κB p65 (C), and inhibitor of NF­κB (IκB) were determined by western blot analysis. The results indicated that POGD significantly inhibited MH7A cell growth. POGD markedly inhibited paw swelling and the arthritis indices of the CIA rats, and POGD may also inhibit the release of pro­inflammatory cytokines. Furthermore, POGD downregulated the expression levels of TGF­ß1, Smad4, NF­κB p65 (N), p38, p­p38, p­ERK1/2, JNK, p­JNK, TGF­ß1, Smad4, p­JNK, JNK, p­P38, P38, p­ERK1/2, ERK1/2 and NF­κB p65 (N), and upregulated the Smad7, NF­κB p65 (C) and IκB in TNF­α induced MH7A cells. In conclusion, the results suggested that POGD is a promising potential anti­inflammatory drug, and that POGD may decrease the expression of pro­inflammatory cytokines and mediators via inhibiting the TGF­ß/NF­κB/mitogen­activated protein kinase pathways.


Asunto(s)
Antiinflamatorios/uso terapéutico , Artritis Experimental/tratamiento farmacológico , Artritis Reumatoide/tratamiento farmacológico , Emodina/análogos & derivados , Glucósidos/uso terapéutico , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Sinoviocitos/efectos de los fármacos , Factor de Crecimiento Transformador beta/inmunología , Animales , Antiinflamatorios/química , Antiinflamatorios/aislamiento & purificación , Artritis Experimental/inmunología , Artritis Experimental/patología , Artritis Reumatoide/inmunología , Artritis Reumatoide/patología , Línea Celular , Proliferación Celular/efectos de los fármacos , Emodina/química , Emodina/aislamiento & purificación , Emodina/uso terapéutico , Fallopia japonica/química , Femenino , Glucósidos/química , Glucósidos/aislamiento & purificación , Interleucinas/inmunología , Masculino , Ratas , Transducción de Señal/efectos de los fármacos , Sinoviocitos/citología , Sinoviocitos/inmunología , Sinoviocitos/patología
14.
Nutr Cancer ; 69(8): 1234-1244, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29043842

RESUMEN

Fucoidan is a sulfated polysaccharide that is extracted from brown algae seaweed. This study was designed to evaluate the protective and immunomodulatory effects of dietary fucoidan on 7,12-dimethyl benz[a]anthracene (DMBA)-induced experimental mammary carcinogenesis in rats. Sixty Sprague-Dawley rats were randomly assigned to four equal groups: the control group (control group), the cancer model group (model group), and the F1 and F2 groups, which were fed fucoidan at concentrations of 200 and 400 mg/kg·body weight, respectively. We found that fucoidan treatment decreased the tumor incidence and mean tumor weight and prolonged the tumor latency. Flow cytometric analyses revealed that the number of blood natural killer cells was higher after fucoidan treatment and that the proportions of CD4 and CD8 T cells were also increased. The serum levels of interleukin (IL)-6, IL-12p40, and interferon (IFN)-γ were higher in the rats treated with fucoidan compared to those of model rats. Moreover, the percentage of CD3+ Foxp3+ regulatory T cells in the blood and the levels of IL-10 and transforming growth factor ß in the serum were lower in the rats treated with fucoidan. Furthermore, fucoidan treatment decreased the expression of Foxp3 and programmed cell death 1 ligand 1 (PDL1) in tumor tissues. The levels of p-phosphatidyl inositol kinase 3 and p-AKT in tumor tissues were also lower than those of model rats. These results suggest that a fucoidan-supplemented diet can inhibit DMBA-induced tumors in rats. This study provides experimental evidence toward elucidating the immune enhancement induced by fucoidan through the programmed cell death 1/PDL1 signaling pathway. The immunomodulatory effect is one of the possible mechanisms of the protective effect of fucoidan against mammary carcinogenesis.


Asunto(s)
Antígeno B7-H1/metabolismo , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Neoplasias Mamarias Experimentales/inmunología , Polisacáridos/farmacología , Receptor de Muerte Celular Programada 1/metabolismo , 9,10-Dimetil-1,2-benzantraceno , Animales , Antígeno B7-H1/genética , Benzo(a)Antracenos , Peso Corporal , Citocinas/sangre , Femenino , Factores de Transcripción Forkhead/genética , Factores de Transcripción Forkhead/metabolismo , Interferón gamma/inmunología , Interleucinas/inmunología , Células Asesinas Naturales/inmunología , Glándulas Mamarias Animales/efectos de los fármacos , Glándulas Mamarias Animales/patología , Neoplasias Mamarias Experimentales/inducido químicamente , Tamaño de los Órganos/efectos de los fármacos , Fosfatidilinositol 3-Quinasas/genética , Fosfatidilinositol 3-Quinasas/metabolismo , Receptor de Muerte Celular Programada 1/genética , Ratas , Ratas Sprague-Dawley , Transducción de Señal , Linfocitos T Reguladores/inmunología , Factor de Crecimiento Transformador beta/inmunología
15.
Nat Med ; 23(9): 1036-1045, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28759052

RESUMEN

D-mannose, a C-2 epimer of glucose, exists naturally in many plants and fruits, and is found in human blood at concentrations less than one-fiftieth of that of glucose. However, although the roles of glucose in T cell metabolism, diabetes and obesity are well characterized, the function of D-mannose in T cell immune responses remains unknown. Here we show that supraphysiological levels of D-mannose safely achievable by drinking-water supplementation suppressed immunopathology in mouse models of autoimmune diabetes and airway inflammation, and increased the proportion of Foxp3+ regulatory T cells (Treg cells) in mice. In vitro, D-mannose stimulated Treg cell differentiation in human and mouse cells by promoting TGF-ß activation, which in turn was mediated by upregulation of integrin αvß8 and reactive oxygen species generated by increased fatty acid oxidation. This previously unrecognized immunoregulatory function of D-mannose may have clinical applications for immunopathology.


Asunto(s)
Colitis/inmunología , Diabetes Mellitus Tipo 1/inmunología , Enfermedades Pulmonares/inmunología , Pulmón/efectos de los fármacos , Manosa/farmacología , Páncreas/efectos de los fármacos , Hipersensibilidad Respiratoria/inmunología , Linfocitos T Reguladores/efectos de los fármacos , Factor de Crecimiento Transformador beta/efectos de los fármacos , Traslado Adoptivo , Animales , Colon/efectos de los fármacos , Suplementos Dietéticos , Modelos Animales de Enfermedad , Ácidos Grasos/metabolismo , Citometría de Flujo , Factores de Transcripción Forkhead/metabolismo , Humanos , Técnicas In Vitro , Inflamación , Integrinas/efectos de los fármacos , Integrinas/inmunología , Metabolismo de los Lípidos/efectos de los fármacos , Pulmón/inmunología , Enfermedades Pulmonares/inducido químicamente , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos NOD , Ovalbúmina/efectos adversos , Oxidación-Reducción/efectos de los fármacos , Páncreas/inmunología , Especies Reactivas de Oxígeno/metabolismo , Reacción en Cadena en Tiempo Real de la Polimerasa , Hipersensibilidad Respiratoria/inducido químicamente , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Bazo/efectos de los fármacos , Bazo/inmunología , Linfocitos T Reguladores/inmunología , Linfocitos T Reguladores/metabolismo , Factor de Crecimiento Transformador beta/inmunología , Regulación hacia Arriba
16.
Hum Vaccin Immunother ; 13(9): 1989-1996, 2017 09 02.
Artículo en Inglés | MEDLINE | ID: mdl-28665747

RESUMEN

An HBsAg-HBIG therapeutic vaccine (Yeast-derived Immune Complexes, YIC) for chronic hepatitis B (CHB) patients has undergone a series of clinical trials. The HBeAg sero-conversion rate of YIC varied from 21.9% to 14% depending on the immunization protocols from 6 to 12 injections. To analyze the immunological mechanisms exerted by 6 injections of YIC, 44 CHB patients were separately immunized with YIC, alum as adjuvant control or normal saline as blank control, with add on of antiviral drug Adefovir in all groups. Kinetic increase in Th1 and Th2 cells CD4+ T cell sub-populations with association in decrease in Treg cells and increase of Tc1 and Tc17 cells in CD8+ T cells were observed in YIC immunized group. No such changes were found in the other groups. By multifunctional analysis of cytokine profiles, significant increase of IL-2 levels was observed, both in CD4+ and CD8+ T cells in the YIC immunized group, accompanied by increase in IFN-gamma and decrease of inhibitory factors (IL-10, TGF-ß and Foxp3) in CD4+ T cells. In the alum immunized group, slight increase of IL-10, TGF-ß and Foxp3 in CD4+ T cells was found after the second injection, but decreased after more injections, suggesting that alum induced early inflammatory responses to a certain extent. Similar patterns of responses of IL-17A and TNF-α in CD8+T cells were shown between YIC and the saline group. Results indicate that add on of Adefovir, did not affect host specific immune responses.


Asunto(s)
Adenina/análogos & derivados , Antígenos de Superficie de la Hepatitis B/inmunología , Vacunas contra Hepatitis B/uso terapéutico , Hepatitis B Crónica/tratamiento farmacológico , Organofosfonatos/uso terapéutico , Adenina/efectos adversos , Adenina/inmunología , Adenina/uso terapéutico , Adyuvantes Inmunológicos , Adulto , Complejo Antígeno-Anticuerpo , Terapia Combinada , Femenino , Vacunas contra Hepatitis B/efectos adversos , Vacunas contra Hepatitis B/inmunología , Hepatitis B Crónica/inmunología , Humanos , Interleucina-10/inmunología , Interleucina-17/inmunología , Interleucina-2/inmunología , Masculino , Organofosfonatos/efectos adversos , Organofosfonatos/inmunología , Células TH1/inmunología , Células Th2/inmunología , Factor de Crecimiento Transformador beta/biosíntesis , Factor de Crecimiento Transformador beta/inmunología , Factor de Necrosis Tumoral alfa/biosíntesis , Factor de Necrosis Tumoral alfa/inmunología , Adulto Joven
17.
Immunology ; 152(1): 52-64, 2017 09.
Artículo en Inglés | MEDLINE | ID: mdl-28423181

RESUMEN

Dendritic cells (DCs) in mesenteric lymph nodes (MLNs) induce Foxp3+ regulatory T cells to regulate immune responses to beneficial or non-harmful agents in the intestine, such as commensal bacteria and foods. Several studies in MLN DCs have revealed that the CD103+ DC subset highly induces regulatory T cells, and another study has reported that MLN DCs from programmed death ligand 1 (PD-L1) -deficient mice could not induce regulatory T cells. Hence, the present study investigated the expression of these molecules on MLN CD11c+ cells. Four distinct subsets expressing CD103 and/or PD-L1 were identified, namely CD11b+ CD103+ PD-L1High , CD11b- CD103+ PD-L1High , CD11b- CD103+ PD-L1Low and CD11b+ CD103- PD-L1Int . Among them, the CD11b- CD103+ PD-L1High DC subset highly induced Foxp3+ T cells. This subset expressed Aldh1a2 and Itgb8 genes, which are involved in retinoic acid metabolism and transforming growth factor-ß (TGF-ß) activation, respectively. Exogenous TGF-ß supplementation equalized the level of Foxp3+ T-cell induction by the four subsets whereas retinoic acid did not, which suggests that high ability to activate TGF-ß is determinant for the high Foxp3+ T-cell induction by CD11b- CD103+ PD-L1High DC subset. Finally, this subset exhibited a migratory DC phenotype and could take up and present orally administered antigens. Collectively, the MLN CD11b- CD103+ PD-L1High DC subset probably takes up luminal antigens in the intestine, migrates to MLNs, and highly induces regulatory T cells through TGF-ß activation.


Asunto(s)
Antígenos CD/inmunología , Antígeno B7-H1/inmunología , Antígeno CD11b/inmunología , Comunicación Celular , Células Dendríticas/inmunología , Cadenas alfa de Integrinas/inmunología , Intestinos/inmunología , Ganglios Linfáticos/inmunología , Linfocitos T Reguladores/inmunología , Administración Oral , Aldehído Deshidrogenasa/inmunología , Aldehído Deshidrogenasa/metabolismo , Familia de Aldehído Deshidrogenasa 1 , Animales , Antígenos CD/metabolismo , Antígeno B7-H1/metabolismo , Antígeno CD11b/metabolismo , Comunicación Celular/efectos de los fármacos , Movimiento Celular , Células Cultivadas , Técnicas de Cocultivo , Células Dendríticas/efectos de los fármacos , Células Dendríticas/metabolismo , Factores de Transcripción Forkhead/inmunología , Factores de Transcripción Forkhead/metabolismo , Inmunidad Mucosa , Cadenas alfa de Integrinas/metabolismo , Cadenas beta de Integrinas/inmunología , Cadenas beta de Integrinas/metabolismo , Mucosa Intestinal/metabolismo , Intestinos/citología , Intestinos/efectos de los fármacos , Ganglios Linfáticos/citología , Ganglios Linfáticos/efectos de los fármacos , Ganglios Linfáticos/metabolismo , Mesenterio , Ratones Endogámicos BALB C , Ovalbúmina/administración & dosificación , Ovalbúmina/inmunología , Fenotipo , Retinal-Deshidrogenasa , Transducción de Señal , Linfocitos T Reguladores/efectos de los fármacos , Linfocitos T Reguladores/metabolismo , Factor de Crecimiento Transformador beta/inmunología , Factor de Crecimiento Transformador beta/metabolismo , Tretinoina/farmacología
18.
BMC Complement Altern Med ; 17(1): 41, 2017 Jan 13.
Artículo en Inglés | MEDLINE | ID: mdl-28086772

RESUMEN

BACKGROUND: Previous studies showed Scutellaria barbata D. Don extract (SBE) is a potent inhibitor in hepatoma and could improve immune function of hepatoma H22-bearing mice. However, the immunomodulatory function of SBE on the tumor growth of hepatoma remains unclear. This study aimed to investigate the anti-tumor effects of SBE on hepatoma H22-bearing mice and explore the underlying immunomodulatory function. METHODS: The hepatoma H22-bearing mice were treated by SBE for 30 days. The effect of SBE on the proliferation of HepG2 cells in vitro, the growth of transplanted tumor, the cytotoxicity of natural killer (NK) cells in spleen, the amount of CD4+CD25+Foxp3+ Treg cells and Th17 cells in tumor tissue, and the levels of IL-10, TGF-ß, IL-17A, IL-2, and IFN-γ in serum of the hepatoma H22-bearing mice was observered. IL-17A was injected to the SBE treated mice from day 9 post H22 inoculation to examine its effect on tumor growth. RESULTS: SBE treatment inhibited the proliferation of HepG2 cells in vitro with a dose-dependent manner and significantly suppressed the tumor growth of hepatoma H22-bearing mice. Meanwhile, it increased NK cells' cytotoxicity in spleen, down-regulated the amount of CD4+CD25+Foxp3+ Treg cells and Th17 cells in tumor tissue, and decreased IL-10, TGF-ß, and IL-17A levels (P < 0.01) whereas increased IL-2 and IFN-γ levels (P < 0.01) in the serum of hepatoma H22-bearing mice. Moreover, administration of recombinant mouse IL-17A reversed the anti-tumor effects of SBE. CONCLUSION: SBE could inhibit the proliferation of HepG2 cells in vitro. Meanwhile, SBE also could inhibit the growth of H22 implanted tumor in hepatoma H22-bearing mice, and this function might be associated with immunomodulatory activity through down-regulating of Treg cells and manipulating Th1/Th17 immune response.


Asunto(s)
Proliferación Celular/efectos de los fármacos , Medicamentos Herbarios Chinos/administración & dosificación , Neoplasias Hepáticas/tratamiento farmacológico , Scutellaria/química , Linfocitos T Reguladores/efectos de los fármacos , Células TH1/efectos de los fármacos , Células Th17/efectos de los fármacos , Animales , Línea Celular Tumoral , Regulación hacia Abajo/efectos de los fármacos , Humanos , Interleucina-10/genética , Interleucina-10/inmunología , Interleucina-17/genética , Interleucina-17/inmunología , Células Asesinas Naturales/efectos de los fármacos , Células Asesinas Naturales/inmunología , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/inmunología , Neoplasias Hepáticas/fisiopatología , Masculino , Ratones , Ratones Endogámicos BALB C , Células TH1/inmunología , Células Th17/inmunología , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/inmunología
19.
Am J Physiol Endocrinol Metab ; 312(3): E161-E174, 2017 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-27894066

RESUMEN

Hypothalamic inflammation was recently found to mediate obesity-related hypertension, but the responsible upstream mediators remain unexplored. In this study, we show that dietary obesity is associated with extracellular release of mitochondrial DNA (mtDNA) into the cerebrospinal fluid and that central delivery of mtDNA mimics transforming growth factor-ß (TGFß) excess to activate downstream signaling pathways. Physiological study reveals that central administration of mtDNA or TGFß is sufficient to cause hypertension in mice. Knockout of the TGFß receptor in proopiomelanocortin neurons counteracts the hypertensive effect of not only TGFß but also mtDNA excess, while the hypertensive action of central mtDNA can be blocked pharmacologically by a TGFß receptor antagonist or genetically by TGFß receptor knockout. Finally, we confirm that obesity-induced hypertension can be reversed through central treatment with TGFß receptor antagonist. In conclusion, circulating mtDNA in the brain employs neural TGFß pathway to mediate a central inflammatory mechanism of obesity-related hypertension.


Asunto(s)
Presión Sanguínea/inmunología , ADN Mitocondrial/inmunología , Hipertensión/inmunología , Hipotálamo/inmunología , Obesidad/inmunología , Proteínas Serina-Treonina Quinasas/genética , Receptores de Factores de Crecimiento Transformadores beta/genética , Factor de Crecimiento Transformador beta/inmunología , Animales , Benzamidas/farmacología , Western Blotting , ADN Mitocondrial/líquido cefalorraquídeo , ADN Mitocondrial/metabolismo , ADN Mitocondrial/farmacología , Dieta Alta en Grasa , Dioxoles/farmacología , Hipertensión/etiología , Hipotálamo/metabolismo , Masculino , Ratones , Ratones Noqueados , Neuronas/inmunología , Neuronas/metabolismo , Obesidad/complicaciones , Proopiomelanocortina/metabolismo , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Proteínas Serina-Treonina Quinasas/inmunología , Receptor Tipo II de Factor de Crecimiento Transformador beta , Receptores de Factores de Crecimiento Transformadores beta/antagonistas & inhibidores , Receptores de Factores de Crecimiento Transformadores beta/inmunología , Tercer Ventrículo , Factor de Crecimiento Transformador beta1/farmacología
20.
J Affect Disord ; 205: 60-68, 2016 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-27414954

RESUMEN

BACKGROUND: Immune system dysfunction is implicated in the pathophysiology of major depression, and is hypothesized to normalize with successful treatment. We aimed to investigate immune dysfunction in melancholic depression and its response to ECT. METHODS: 55 melancholic depressed patients and 26 controls participated. 33 patients (60%) were referred for ECT. Blood samples were taken at baseline, one hour after the first ECT session, and 48h after ECT series completion. RESULTS: At baseline, melancholic depressed patients had significantly higher levels of the pro-inflammatory cytokine IL-6, and lower levels of the regulatory cytokine TGF-ß than controls. A significant surge in IL-6 levels was observed one hour after the first ECT session, but neither IL-6 nor TGF-ß levels normalized after completion of ECT series. Seventy per cent (n=23) of ECT recipients showed clinical response and 42% (n=10) reached remission. Neither IL-6 nor TGF-ß changes correlated with clinical improvement following ECT. No significant changes in IL-10, TNF-α and CRP levels were found in relation to melancholia or response to ECT. LIMITATIONS: As a naturalistic study, some potential confounders could not be eliminated or controlled, including medication use. CONCLUSIONS: Melancholic depressed patients demonstrated a peripheral increase in IL-6 and reduction in TGF-ß, which did not normalize despite clinical response to ECT. These findings may be consistent with emerging hypotheses of the role of inflammation in mediating neurotrophin expression. The implications of chronic inflammation in the melancholic depressed population for future medical health, particularly cardiovascular risk, are largely unknown and warrant further investigation.


Asunto(s)
Trastorno Depresivo Mayor/terapia , Terapia Electroconvulsiva , Adulto , Anciano , Biomarcadores , Proteína C-Reactiva/inmunología , Citocinas/inmunología , Trastorno Depresivo/inmunología , Trastorno Depresivo/psicología , Trastorno Depresivo/terapia , Trastorno Depresivo Mayor/inmunología , Trastorno Depresivo Mayor/psicología , Femenino , Humanos , Interleucina-10/inmunología , Interleucina-6/inmunología , Masculino , Persona de Mediana Edad , Factor de Crecimiento Transformador beta/inmunología , Resultado del Tratamiento , Factor de Necrosis Tumoral alfa/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA